International Research Grants in Congenital Muscular Dystrophy
Forecasted
International Research Grants in Congenital Muscular Dystrophy support researchers studying congenital onset laminopathies and dystroglycanopathies to advance treatments, disease understanding, and trial readiness.
Funder: Cure CMD
Due Dates (Anticipated): July 2027 (LOI) | September 2027 (Invited full proposal)
Funding Amounts: L-CMD: up to $100,000 over up to two years | αDG: up to $50,000 over up to two years
Summary: Supports international research on congenital onset laminopathies and dystroglycanopathies to advance disease understanding, therapeutic development, and clinical trial readiness.
Key Information: Applicants must hold an MD, PhD, or equivalent and lead an independent laboratory at an accredited institution.
Description
Cure CMD’s International Research Grants support research on congenital onset laminopathies (L-CMD) and congenital onset dystroglycanopathies (αDG). The program seeks work that clarifies disease mechanisms, identifies therapeutic targets, develops preclinical interventions, and moves promising approaches toward clinical application. Its broader goal is to translate research into treatments or improved care for people living with congenital muscular dystrophy.
L-CMD funding particularly prioritizes cardiac complications, including cardiomyopathy and conduction defects, while skeletal muscle research remains within scope. For αDG, Cure CMD strongly encourages cognitive and neural research, alone or alongside muscle-directed approaches, and welcomes therapies with applicability across associated genes. Both streams support disease models, biomarkers, and outcome measures that strengthen therapeutic assessment and clinical trial readiness.
